|Bid||0.00 x 1300|
|Ask||0.00 x 900|
|Day's Range||26.76 - 27.84|
|52 Week Range||24.45 - 41.57|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.18|
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
The Medicines Company (MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification. The IDMC’s recommendation was based on its planned review of unblinded safety and efficacy data from the trials. The ORION Phase III studies with 18-months follow up were fully enrolled between November 2017 and March 2018, with 3,660 patients randomized 1:1 across three trials – ORION-9 (482 patients randomized), ORION-10 (1,561 patients randomized) and ORION-11 (1,617 patients randomized) – to receive either inclisiran or placebo.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios. Olin Corp. (OLN) is trading around $30.27 with a price-sales ratio of 0.8, a price-earnings ratio of 8.2 and a forward price-earnings ratio of 11.6. The company has a market cap of $5.06 billion and the stock price has risen at an annualized rate of 5% over the last 10 years.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnLink ...
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Medicines Co. (MDCO) delivered earnings and revenue surprises of 1.56% and -78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 74 cents per share. Losses, adjusted for one-time gains and costs, were 63 cents per share. The results beat Wall Street expectations. The ...
Medicines Co. (MDCO) reported second-quarter financial results early Wednesday, including a smaller-than-expected profit loss and a revenue miss. Medicines Co. had $162.5 million in cash and cash equivalents as of June 30, compared with $515.4 million at the end of last year.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Medicines Company (NASDAQ: MDCO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. ...